AWARD NUMBER: W81XWH-09-1-0092

TITLE: Telepharmacy Robotic Medicine Delivery Unit "TRMDU" Assessment

PRINCIPAL INVESTIGATOR: Daniel Touchette

CONTRACTING ORGANIZATION: INRange Systems, Inc.

Altoona, PA 16602

REPORT DATE: December 2010

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

this burden to Department of D 4302. Respondents should be	efense, Washington Headquar aware that notwithstanding an	ters Services, Directorate for Info	mation Operations and Reports on shall be subject to any penalty to	0704-0188), 1215 Jeffer	rson Davis Highway, Suite 1204, Arlington, VA 22202- a collection of information if it does not display a currently		
1. REPORT DATE		IR FORM TO THE ABOVE ADDI 2. REPORT TYPE	RESS.	3 D.	ATES COVERED		
1 December 2010		Annual			Nov 2009 – 25 Nov 2010		
4. TITLE AND SUBTIT		Allitual			CONTRACT NUMBER		
4. IIILL AND SOUTH	LL .			Ja. V	SONTRACT NOMBER		
-				FI. A	ODANT NUMBER		
Telepharmacy Rob	Telepharmacy Robotic Medicine Delivery Unit "TRMDU" A				GRANT NUMBER		
				844	1XWH-09-1-0092		
				50.5	PROGRAM ELEMENT NUMBER		
				5C. F	PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)				5d. F	PROJECT NUMBER		
<i>、,</i>							
Daniel Touchette				5e. 7	TASK NUMBER		
E-Mail: drtouche@	ປີuic.edu			5f. V	VORK UNIT NUMBER		
	9						
7. PERFORMING ORG	ANIZATION NAME(S)	AND ADDRESS(ES)		8. PI	ERFORMING ORGANIZATION REPORT		
INRange Systems					UMBER		
Altoona, PA 16602							
A110011a, 1 A 10002	•						
9. SPONSORING / MO	NITORING AGENCY N	IAME(S) AND ADDRES	S(ES)	10. 9	SPONSOR/MONITOR'S ACRONYM(S)		
U.S. Army Medica			` ,		• •		
Fort Detrick, Maryl							
Tore Bouron, Mary	ana 21702 0012			11 9	SPONSOR/MONITOR'S REPORT		
					NUMBER(S)		
				'	NOMBER(3)		
12. DISTRIBUTION / A	VAII ARII ITY STATEN	/FNT					
Approved for Publi							
13. SUPPLEMENTAR	•						
13. SUPPLEMENTAR	INUIES						
14. ABSTRACT							
	ncreasing number of	patients with combat-	elated impairments th	at contribute to s	suboptimal medication self-		
					icant number of these patients are in		
					services. The objective of this study is		
to evaluate whether the use of a TelePharmacy robotic remote medication dispensing unit (TRMDU), in addition to medication review in patients assigned to WTUs, VA hospitals, and similar units, leads to improved outcomes and reduced health care costs for patients when							
compared with medication review alone. This study will use a prospective non-randomized repeated measures design with two sites using a							
control condition for 12 weeks, followed by a 12-week TRMDU intervention condition. The third site will serve as intervention only.							
Solid of Solid and 12 woods, followed by a 12 wood Trainer intervention contained. The unit site will serve as intervention only.							
15. SUBJECT TERMS							
None provided.							
p							
40.0001101011011011	IEIO ATION OF		4= 1 150-4-1	40 11:	40. NAME OF THE OWNER OWN		
16. SECURITY CLASSIFICATION OF:			17. LIMITATION	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON		
			OF ABSTRACT	OF PAGES	USAMRMC		
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area		
			l	_			
U	U	U	l UU	7	code)		

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the

REPORT DOCUMENTATION PAGE

Form Approved

OMB No. 0704-0188

Table of Contents

Introduction	
Body4	
Key Research Accomplishments	5
Reportable Outcomes	6
Conclusion	6
References	
Appendices	Non

INTRODUCTION

This study involves a FDA cleared remote medication management device, 21 CFR 880.6315, which provides unit dose delivery of medications across the continuum of care. The Telepharmacy Robotic Medication Dispensing Unit (TRMDU), developed by INRange[®] Systems, Inc., is a Class II medical device, located in the home, outpatient setting, or in the field, and consists of a medication delivery unit and two-way communication software that allows a health care professional to remotely manage prescriptions stored and released by the patient-operated delivery unit. The delivery unit is approximately the size of a bread box, and it plugs into a standard power outlet.

We have continued to develop the protocol that will assess this TRMDU unit in subjects with traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), multiple traumatic brain injury (MTBI), or Polytrauma. The objective of this study is to evaluate whether use of a TRMDU, in addition to medication review in patients assigned to WTUs, VA hospitals, and similar units, leads to improved outcomes and reduced health care costs for patients when compared with medication review alone.

BODY

IRB Preparation and Application (Jan 2010 – Dec 2010)

The study was approved by institutional IRB's at the University of Illinois at Chicago on March 25, 2010 and Columbia College of Nursing on October 25, 2010. It was submitted for review to the IRB at NMSCD for the Camp Pendleton site on September 16, 2010, undergone a preliminary review, and has been resubmitted.

Ongoing Study Site Recruitment, Visits, and Development (Jan 2010 – Dec 2010)

The program implementation and evaluation will still be conducted at three sites: 1) James A. Haley VA Hospital and Polytrauma Facility in Tampa Bay, Florida (Tampa VA); 2) Naval Hospital Camp Pendleton, in Camp Pendleton, California (Camp Pendleton); and 3) Ireland Army Community Hospital, Fort Knox, Kentucky (Fort Knox).

A CRADA was prepared between TATRC and Naval Hospital Camp Pendleton outlining the site responsibilities and support. A staffing management plan was prepared to support the CRADA. The CRADA was signed and executed on June 24, 2010.

Planning committee meetings were held in Atlanta on March 1, 2010 and San Antonio on May 19, 2010. During the Atlanta meeting, the discussion focused primarily on study progress and budget. Discussions also focused on next steps, such as hiring of site research personnel, delivery and preparation of the TRMDU's, and study impact on sites. DIACAP certification of the TRMDU (EMMA®) System is a requirement of the TRMDU study, and progress towards obtaining this certification was discussed at the Atlanta and San Antonio meetings. Presently, INRange is in the final review stages of our Navy DIACAP C&A (Certification and Accreditation Process) package with the Navy Information Assurance team, and expects final approval early 2011.

At the San Antonio meeting study progress and budget were once again addressed and committee members updated on study progress. Discussions were held on the transfer of Naval Hospital Camp Pendleton site PI status from LCDR Caine Kras to Angelica Klinski. Also discussed were details regarding TRMDU use, general procedures for repackaging medications, and site research assistance clearance and training. Dr. Touchette, Dr. Winters, and LCDR Klinski attended a site visit at Fort Carson on September 22, 2010 to view the TRMDU in use and talk with clinicians and patients who

were using the device. Valuable insights were gained regarding the importance of standardizing TRMDU settings, information contained in TRMDU reports, and development of the policy and procedures for optimizing the TRMDU during the study. A site visit to Camp Pendleton was conducted on August 31, 2010 with the goal of completing the site IRB application and addressing any issues identified by LCDR Klinski.

Protocol

No significant changes were made to the protocol during the period Dec 25, 2009 – Dec 25, 2010. A copy of the current study protocol is appended to this report.

CRADA and Statement of Work (Jan 2010 - Jun 2010)

A CRADA was developed outlining the 1) background; 2) roles, responsibilities, and relationships of TATRC, Naval Hospital Camp Pendleton, NMCSD, and INRange; and 3) ownership and use of physical property for the TRMDU study. Additional articles included termination, contacts, security, use of protected health information, and liability. The agreement also contained an appendix outlining the activities that will be conducted at the Naval Hospital Camp Pendleton site by research assistants and the necessary support for conducting the study. The CRADA is appended to this report.

DIACAP Preparation and Submission

INRange commenced preparation of a comprehensive DIACAP C&A package Q2/2009. At the present time, the following items, artifacts and activities have been submitted and are being reviewed by the Navy Information Assurance team:

- System Identification Profile (SIP)
- DITSCAP baseline documentation
- Navy POA&M (Plan of Action and Milestones)
- Continuity of Operations Plan (COOP)
- Disaster Recovery "Table Top" exercise
- Enclave and system diagrams
- All servers have been locked down to STIG compliance and scanned with Retina
- Remediation of CAT 1 and Cat 2 Retina scan findings
- All required artifacts have been submitted
- Data Center On-site Audit completed
- Incident Response Plan (made available to auditor)

KEY RESEARCH ACCOMPLISHMENTS

To date, the following has been completed:

- Protocol
- Identification of the participating sites
- Obtaining required approvals and contracts for Naval Hospital Camp Pendleton
- Gaining IRB approval at University of Illinois at Chicago and Columbia College of Nursing

To date, we have made considerable progress in the following:

- Preparation and submission of the IRB documents to Naval Hospital Camp Pendleton
- Preparation of IRB documents for Fort Detrick submission

REPORTABLE OUTCOMES

We are currently pursuing approval to begin the study. At present there are no reportable outcomes. We expect that, when completed, this study will generate at least one and possibly two manuscripts on the effectiveness of the TRMDU on adherence and outcomes assessed in this study for this population. Publication of these manuscripts will be pursued in major, peer-reviewed medical journals.

CONCLUSION

Findings from several studies have shown that better medication adherence leads to better outcomes, fewer hospitalizations and emergency department visits, and greater QOL. Use of the TRMDU may improve medication adherence; reduce DRPs; and positively impact pain, psychological, and QOL measures for veterans with TBI, PTSD, and/or polytrauma. In addition, health care costs and hospitalizations may be reduced. If findings from this study support the hypotheses, use of the TRMDU may be a valuable intervention and lay the groundwork for applications of the TRMDU with this population in both the Warrior Transition Units and in community settings. In addition, those individuals in rural settings with limited access to major medical centers and other populations with documented difficulty with medication adherence may benefit from such a device. This study will serve to lay the groundwork for additional funding to assess the effectiveness of the TRMDU in these settings.

REFERENCES

- Bates, D. W. (2007). "Preventing medication errors: a summary." <u>Am J Health Syst Pharm</u> **64**(14 Suppl 9): S3-9; quiz S24-6.
- Cantor, J. B., T. Ashman, et al. (2008). "Fatigue after traumatic brain injury and its impact on participation and quality of life." <u>J Head Trauma Rehabil</u> 23(1): 41-51.
- Ernst, F. R. and A. J. Grizzle (2001). "Drug-related morbidity and mortality: updating the cost-of-illness model." J Am Pharm Assoc (Wash) **41**(2): 192-9.
- Folstein, M. F., S. E. Folstein, et al. (1975). ""Mini-mental state". A practical method for grading the cognitive state of patients for the clinician." <u>J Psychiatr Res</u> **12**(3): 189-98.
- Hoge, C. W., C. A. Castro, et al. (2004). "Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care." N Engl J Med 351(1): 13-22.
- Institute for Healthcare Improvement. (2009). "Prevent adverse drug events (medication reconciliation)." Retrieved June 22, 2009, from http://www.ihi.org/IHI/Programs/Campaign/ADEsMedReconciliation.htm.
- Institute of Medicine (2007). <u>Preventing medication errors: quality chasm series</u>. Washington, DC, National Academy Press.
- Krousel-Wood, M., T. Islam, et al. (2009). "New medication adherence scale versus pharmacy fill rates in seniors with hypertension." Am J Manag Care 15(1): 59-66.
- Lee, J. K., K. A. Grace, et al. (2006). "Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial." JAMA 296(21): 2563-71.
- McDonald, H. P., A. X. Garg, et al. (2002). "Interventions to enhance patient adherence to medication prescriptions: scientific review." <u>JAMA</u> **288**(22): 2868-79.
- McNair, D., M. Lorr, et al. (1992). POMS Manual. North Tonawanda, New York, MHS.
- Melzack, R. (1987). "The short-form McGill Pain Questionnaire." Pain 30(2): 191-7.

- Morisky, D. E., A. Ang, et al. (2008). "Predictive validity of a medication adherence measure in an outpatient setting." <u>J Clin Hypertens (Greenwich)</u> **10**(5): 348-54.
- Nathan, A., L. Goodyer, et al. (1999). "Brown bag' medication reviews as a means of optimizing patients' use of medication and of identifying potential clinical problems." Fam Pract 16(3): 278-82.
- National Council on Patient Information and Education. (2008). "Public policy & adherence." Retrieved July 20, 2008, from
 - $\underline{http://www.talkaboutrx.org/documents/enhancing_prescription_medicine_adherence.pdf}.$
- O'Connor, P. J. (2006). "Improving medication adherence: challenges for physicians, payers, and policy makers." <u>Arch Intern Med</u> **166**(17): 1802-4.
- Osterberg, L. and T. Blaschke (2005). "Adherence to medication." N Engl J Med 353(5): 487-97.
- Sakthong, P., R. Chabunthom, et al. (2009). "Psychometric properties of the Thai version of the 8-item Morisky Medication Adherence Scale in patients with type 2 diabetes." <u>Ann Pharmacother</u> **43**(5): 950-7.
- Svarstad, B. L., B. A. Chewning, et al. (1999). "The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence." <u>Patient Educ Couns</u> **37**(2): 113-24.
- Touchette, D. R., A. L. Burns, et al. (2006). "Survey of medication therapy management programs under Medicare part D." J Am Pharm Assoc (2003) 46(6): 683-91.
- van Mil, J. W., L. O. Westerlund, et al. (2004). "Drug-related problem classification systems." <u>Ann Pharmacother</u> **38**(5): 859-67.
- Vasterling, J. J., S. P. Proctor, et al. (2006). "Neuropsychological outcomes of army personnel following deployment to the Iraq war." <u>JAMA</u> **296**(5): 519-29.
- Ware, J. E., K. K. Snow, et al. (1993). <u>SF36 health survey: Manual and interpretation guide</u>. Boston. MA, New England Medical Center.
- World Health Organization (2003). <u>Adherence to long-term therapies: evidence for action.</u> Geneva, Switzerland, WHO.